STOCK TITAN

Personalis, Inc. - PSNL STOCK NEWS

Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.

Personalis, Inc. (symbol: PSNL) is a leading genome-scale diagnostics company dedicated to advancing the field of genome-guided medicine. The company's mission is to extract the most accurate genetic data from each sample and draw reliable, medically-focused conclusions. Personalis leverages cutting-edge whole genome and exome sequencing techniques, conducted in their state-of-the-art laboratory, to provide comprehensive insights.

Personalis offers a range of products and services designed to support academic, pharmaceutical, and biotech researchers. Their flagship products include ImmunoID NeXT, NeXT Personal, and NeXT Dx Test, which cater to diverse needs including personalized cancer vaccines and next-generation cancer immunotherapies. Additionally, their solutions serve those engaged in large case-control and family-based genome studies of complex or Mendelian diseases, pharmacogenomics, and cancer research.

Their proprietary databases, advanced human reference sequences, and sophisticated algorithms ensure accurate and comprehensive end-to-end human genome sequencing and analysis. Personalis' commitment to quality and innovation positions them as a critical player in the evolving landscape of genomic medicine.

Recent achievements include partnerships with key pharmaceutical companies to enhance the development of personalized cancer treatments. The company continues to innovate and expand its service offerings, ensuring researchers and clinicians have access to the most advanced tools for genomic analysis.

For those seeking the latest updates and relevant information on Personalis, Inc., StockTitan provides a comprehensive list of news and developments, ensuring investors and stakeholders stay informed on this pioneering company's performance and advancements.

Rhea-AI Summary

On September 13, 2022, at 1:30 p.m. Eastern Time, Personalis, Inc. (NASDAQ: PSNL) will present at the Morgan Stanley 20th Annual Global Healthcare Conference in New York, NY. As a leader in advanced cancer genomics, Personalis offers innovative solutions for precision cancer therapies and diagnostics through its Personalis NeXT Platform. The company's Clinical Laboratory is recognized for its accuracy, quality, and efficiency, complying with industry standards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
conferences
-
Rhea-AI Summary

Personalis, Inc. (NASDAQ: PSNL) announced the filing of an amended complaint against Foresight Diagnostics, claiming infringement of its newly issued US Patent No. 11,408,033. This patent strengthens Personalis' position in the molecular residual disease (MRD) testing space. The patent enables personalized MRD panels, utilizing tumor-informed and database-derived content for enhanced cancer detection. Personalis seeks injunctive relief and damages from Foresight’s alleged infringement, reinforcing its commitment to protect its intellectual property as it expands its advanced cancer genomics capabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
none
-
Rhea-AI Summary

Personalis, Inc. (NASDAQ: PSNL) announced on August 15, 2022, that its Compensation Committee granted non-qualified stock options and restricted stock units (RSUs) totaling 70,000 shares each to two new employees under its 2020 Inducement Plan. The stock options have an exercise price of $5.32 per share, aligning with the closing stock price on the grant date. Vested options and RSUs will occur over four years. This grant complies with Nasdaq rules and is aimed at attracting talent to enhance the company's growth in advanced cancer genomics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.08%
Tags
none
Rhea-AI Summary

Personalis has announced a collaboration with BC Cancer to implement the NeXT Personal liquid biopsy assay in a study focused on colorectal and pancreatic cancers. This personalized assay aims to enhance molecular residual disease (MRD) detection by analyzing circulating tumor DNA (ctDNA) from blood samples. The study will enroll approximately 220 patients across British Columbia and seek to evaluate cost-effectiveness compared to traditional imaging methods. Insights from this research could significantly impact cancer management and patient survival.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
partnership
-
Rhea-AI Summary

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced cancer genomics, announced its participation in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 16, 2022. This event will feature the management team discussing innovations in precision cancer therapies and diagnostics through the Personalis NeXT Platform, which analyzes the full spectrum of human genes and immune system data.

Personalis' Clinical Laboratory is GxP-aligned and certified, emphasizing clinical accuracy and efficiency.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.22%
Tags
conferences
-
Rhea-AI Summary

Personalis, Inc. (PSNL) reported Q2 2022 results, with revenues of $18.2 million, down from $21.7 million in Q2 2021. Revenue from biopharma customers rose by 74% to $14.2 million, boosted by $6.8 million from Natera. VA MVP revenues fell sharply to $4.0 million from $13.5 million year-over-year. The company incurred a net loss of $27.5 million and anticipates total 2022 revenues between $62.0 million to $67.0 million. Notably, cash reserves were strong at $233.5 million as of June 30, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
Rhea-AI Summary

Personalis, Inc. (Nasdaq: PSNL) has filed a lawsuit against Foresight Diagnostics Inc. for infringing its U.S. Patent Nos. 10,450,611, 11,299,783, and 11,384,394, central to its tumor-informed molecular residual disease (MRD) testing innovations. This legal action seeks both injunctive relief and monetary damages. Personalis emphasizes its long-standing expertise in whole genome sequencing, asserting that its NeXT Personal MRD solution represents a significant advancement in cancer detection, achieving unmatched sensitivity in identifying residual cancer cells.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.07%
Tags
none
-
Rhea-AI Summary

Personalis, Inc. (NASDAQ: PSNL) will release its second quarter 2022 financial results on August 3, 2022. The company will also host a conference call and webcast at 2:00 p.m. PT to discuss financial outcomes and recent developments. Interested participants can register for the call via the provided link and access the live webinar on the company's website. Personalis is recognized for its advancements in cancer genomics, playing a pivotal role in precision oncology through the Personalis NeXT Platform®.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
-
Rhea-AI Summary

Personalis, Inc. (NASDAQ: PSNL) has added a new patent to its molecular residual disease (MRD) IP portfolio, issued on January 2013, focusing on tumor detection through whole genome sequencing. The newly granted US Patent No. 11,384,394 enhances the NeXT Personal™ platform, allowing for highly sensitive measurement of tumor burden. This patent strengthens Personalis' position in advanced genomic analysis with 21 issued patents and over 30 pending applications related to cancer detection and genomic sequencing. The approach could lead to earlier detection of cancer recurrence and improved treatment options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.92%
Tags
none
Rhea-AI Summary

Personalis, Inc. (Nasdaq: PSNL) reported Q1 2022 financial results with revenue of $15.2 million, down from $20.9 million in Q1 2021. Revenue from biopharma customers increased by 53% to $11.7 million, including $4.1 million from Natera. Revenue from the VA MVP dropped to $3.5 million from $13.2 million in the prior year. The company expects full-year 2022 revenue between $62.0 million and $67.0 million, with a projected net loss of $110.0 million to $115.0 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.88%
Tags

FAQ

What is the current stock price of Personalis (PSNL)?

The current stock price of Personalis (PSNL) is $5.75 as of December 20, 2024.

What is the market cap of Personalis (PSNL)?

The market cap of Personalis (PSNL) is approximately 474.6M.

What does Personalis, Inc. specialize in?

Personalis, Inc. specializes in genome-scale diagnostics and genome-guided medicine.

What are Personalis' main products?

Their main products include ImmunoID NeXT, NeXT Personal, and NeXT Dx Test.

Who can benefit from Personalis' services?

Academic, pharmaceutical, and biotech researchers engaged in genome studies, pharmacogenomics, and cancer research can benefit from their services.

What technologies does Personalis use?

Personalis uses whole genome and exome sequencing, proprietary databases, human reference sequences, and sophisticated algorithms.

What is the mission of Personalis, Inc.?

The mission of Personalis is to pioneer genome-guided medicine by obtaining accurate genetic data and drawing reliable, medically-focused conclusions.

How does Personalis support cancer research?

Personalis provides genomic sequencing and analytics solutions that support the development of personalized cancer vaccines and next-generation cancer immunotherapies.

What recent achievements has Personalis made?

Personalis has formed key partnerships with pharmaceutical companies to advance personalized cancer treatments.

What sets Personalis apart from other genomic companies?

Personalis' comprehensive end-to-end genome sequencing and analysis solutions, coupled with their proprietary technologies, set them apart.

Why is genome sequencing important in medical research?

Genome sequencing is crucial for understanding genetic factors in diseases, enabling the development of targeted treatments and personalized medicine.

How can I stay updated on Personalis' latest news?

You can stay updated on Personalis' latest news by following their updates on StockTitan and other financial news platforms.

Personalis, Inc.

Nasdaq:PSNL

PSNL Rankings

PSNL Stock Data

474.58M
54.05M
19.3%
53.16%
4.04%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
FREMONT